GRECCAR 14 - a multicentric, randomized, phase II-III study evaluating the tailored management of locally advanced rectal carcinoma after a favourable response to induction chemotherapy: Study protocol.
Humans
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma
/ pathology
Chemoradiotherapy
/ methods
Clinical Trials, Phase II as Topic
Neoadjuvant Therapy
/ methods
Neoplasm Staging
Pancreatic Neoplasms
/ drug therapy
Randomized Controlled Trials as Topic
Rectal Neoplasms
/ drug therapy
Rectum
/ surgery
Treatment Outcome
Multicenter Studies as Topic
Clinical Trials, Phase III as Topic
Equivalence Trials as Topic
Journal
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
ISSN: 1463-1318
Titre abrégé: Colorectal Dis
Pays: England
ID NLM: 100883611
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
27
07
2023
received:
19
05
2023
accepted:
03
08
2023
medline:
1
11
2023
pubmed:
12
9
2023
entrez:
12
9
2023
Statut:
ppublish
Résumé
Total neoadjuvant treatment (TNT) is becoming standard in patients with locally advanced rectal carcinoma (LARC). Preoperative chemoradiotherapy (CRT) has proven side effects on bowel and genitourinary function. An early tumoral response to induction chemotherapy demonstrates its high prognostic value. Tailored management could be used as an alternative to systematic CRT. The GRECCAR 14 trial will attempt to personalize treatment strategy according to the patient's early tumour response to intensive chemotherapy with the aim of achieving the best toxicity-efficiency ratio. GRECCAR 14 is a multicentric, randomized, two-arm, phase II-III noninferiority trial. Patients with mid or low LARC with a predictive circumferential resection margin ≤2 mm or T3c-d stage with extramural venous invasion will be included. Evaluation of the tumoral response will be performed after six courses of high-dose FOLFIRINOX chemotherapy. Good responders (GRs) will be defined by a 60% decrease in tumoral volume on magnetic resonance imaging. Patients will be randomized to CRT before surgery. The primary endpoints will be R0 resection for phase II and the 3-year disease-free survival (DFS) for phase III. Tailored management of LARC is becoming an exciting challenge for the modality of neoadjuvant treatment and for the type of surgery or its omission. Neoadjuvant FOLFIRINOX has established efficacy, with a significant increase in the 3-year DFS. Better control of systemic disease must be accompanied by the same locoregional control, with the lowest morbidity. Our previous GRECCAR 4 trial demonstrated the high value of the early tumoral response after induction chemotherapy and the long-term safety of tailored management for GRs. If GRECCAR 14 demonstrates the ability to tailor TNT for LARC, this could lead to changes in clinical practice.
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2078-2086Subventions
Organisme : PHRC-K-2020
Informations de copyright
© 2023 Association of Coloproctology of Great Britain and Ireland.
Références
Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, et al. NACT with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702-715. https://doi.org/10.1016/s1470-2045(21)00079-6
Shi DD, Mamon HJ. Playing with dynamite? A cautious assessment of TNT. J Clin Oncol. 2021;39(2):103-106. https://doi.org/10.1200/jco.20.02199
Anker CJ, Lester-Coll NH, Akselrod D, Cataldo PA, Ades S. The potential for overtreatment with total neoadjuvant therapy (TNT): consider one local therapy instead. Clin Colorectal Cancer. 2022;21(1):19-35. https://doi.org/10.1016/j.clcc.2021.11.001
Rullier E, Vendrely V, Asselineau J, Rouanet P, Tuech JJ, Valverde A, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 2020;5(5):465-474. https://doi.org/10.1016/s2468-1253(19)30410-8
Smith JJ, Chow OS, Gollub MJ, Nash GM, Temple LK, Weiser MR, et al. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767. https://doi.org/10.1186/s12885-015-1632-z
Zwart WH, Hotca A, Hospers GAP, Goodman KA, Garcia-Aguilar J. The multimodal management of locally advanced rectal cancer: making sense of the new data. Am Soc Clin Oncol Educ Book. 2022;42:1-14. https://doi.org/10.1200/edbk_351411
Sun W, Dou R, Chen J, Lai S, Zhang C, Ruan L, et al. Impact of long-course neoadjuvant radiation on postoperative low anterior resection syndrome and quality of life in rectal cancer: post hoc analysis of a randomized controlled trial. Ann Surg Oncol. 2019;26(3):746-755. https://doi.org/10.1245/s10434-018-07096-8
Chen TY, Wiltink LM, Nout RA, Meershoek-Klein KE, Laurberg S, Marijnen CA, et al. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. Clin Colorectal Cancer. 2015;14(2):106-114. https://doi.org/10.1016/j.clcc.2014.12.007
Qin Q, Ma T, Deng Y, Zheng J, Zhou Z, Wang H, et al. Impact of preoperative radiotherapy on anastomotic leakage and stenosis after rectal cancer resection: post hoc analysis of a randomized controlled trial. Dis Colon Rectum. 2016;59(10):934-942. https://doi.org/10.1097/dcr.0000000000000665
Azria D, Doyen J, Jarlier M, Martel-Lafay I, Hennequin C, Etienne P, et al. Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. Ann Oncol. 2017;28(10):2436-2442. https://doi.org/10.1093/annonc/mdx351
van der Sande ME, Hupkens BJP, Berbée M, van Kuijk SMJ, Maas M, Melenhorst J, et al. Impact of radiotherapy on anorectal function in patients with rectal cancer following a watch and wait programme. Radiother Oncol. 2019;132:79-84. https://doi.org/10.1016/j.radonc.2018.11.017
Kong M, Chen H, Shan K, Sheng H, Li L. Comparison of survival among adults with rectal cancer who have undergone laparoscopic vs open surgery: a meta-analysis. JAMA Netw Open. 2022;5(5):e2210861. https://doi.org/10.1001/jamanetworkopen.2022.10861
Ryan OK, Ryan ÉJ, Creavin B, Rausa E, Kelly ME, Petrelli F, et al. Surgical approach for rectal cancer: a network meta-analysis comparing open, laparoscopic, robotic and transanal TME approaches. Eur J Surg Oncol. 2021;47(2):285-295. https://doi.org/10.1016/j.ejso.2020.06.037
Yang B, Zhang S, Yang X, Wang Y, Li D, Zhao J, et al. Analysis of bowel function, urogenital function, and long-term follow-up outcomes associated with robotic and laparoscopic sphincter-preserving surgical approaches to total mesorectal excision in low rectal cancer: a retrospective cohort study. World J Surg Oncol. 2022;20(1):167. https://doi.org/10.1186/s12957-022-02631-0
Patel UB, Blomqvist L, Chau I, Nicholls J, Brown G. Session 3: beyond TME and radiotherapy MRI evaluation of rectal cancer treatment response. Colorectal Dis. 2018;20(Suppl 1):76-81. https://doi.org/10.1111/codi.14084
Schrag D, Shi Q, Weiser M, Gollub M, Saltz L, Musher B, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med. 2023;389:322-334. https://doi.org/10.1056/NEJMoa2303269
Rouanet P, Rullier E, Lelong B, Maingon P, Tuech JJ, Pezet D, et al. Tailored treatment strategy for locally advanced rectal carcinoma based on the tumor response to induction chemotherapy: preliminary results of the French phase II multicenter GRECCAR4 trial. Dis Colon Rectum. 2017;60(7):653-663. https://doi.org/10.1097/dcr.0000000000000849
Rouanet P, Rullier E, Lelong B, Maingon P, Tuech JJ, Pezet D, et al. Tailored strategy for locally advanced rectal carcinoma (GRECCAR 4): long-term results from a multicenter, randomized, open-label, phase II trial. Dis Colon Rectum. 2022;65(8):986-995. https://doi.org/10.1097/dcr.0000000000002153
Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(10):1139-1167. https://doi.org/10.6004/jnccn.2022.0051
Bahadoer RR, Peeters K, Beets GL, Figueiredo NL, Bastiaannet E, Vahrmeijer A, et al. Watch and wait after a clinical complete response in rectal cancer patients younger than 50 years. Br J Surg. 2021;109(1):114-120. https://doi.org/10.1093/bjs/znab372
Glynne-Jones R, Harrison M, Cheetham D. NICE guideline for rectal cancer: already out of date. Lancet. 2020;395(10240):e105-e106. https://doi.org/10.1016/s0140-6736(20)30855-2
Wo JY, Anker CJ, Ashman JB, Bhadkamkar NA, Bradfield L, Chang DT, et al. Radiation therapy for rectal cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2021;11(1):13-25. https://doi.org/10.1016/j.prro.2020.08.004
Lin H, Wang L, Zhong X, Zhang X, Shao L, Wu J. Meta-analysis of NACT versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer. World J Surg Oncol. 2021;19(1):141. https://doi.org/10.1186/s12957-021-02251-0
Wu P, Xu HM, Zhu Z. NACT without radiation as a potential alternative treatment for locally advanced rectal cancer: a meta-analysis. World J Gastrointest Oncol. 2021;13(9):1196-1209. https://doi.org/10.4251/wjgo.v13.i9.1196
Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638-646. https://doi.org/10.1056/NEJMoa010580
Abraha I, Aristei C, Palumbo I, Lupattelli M, Trastulli S, Cirocchi R, et al. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. Cochrane Database Syst Rev. 2018;10(10):CD002102. https://doi.org/10.1002/14651858.CD002102.pub3
Lee KH, Kim JS, Kim JY. Omission of neoadjuvant radiotherapy for clinical T2/N1 and T3N0/1 middle and low rectal cancers with safe circumferential resection margins. Ann Surg Treat Res. 2022;102(5):281-288. https://doi.org/10.4174/astr.2022.102.5.281
Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G, et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76(4):1005-1011. https://doi.org/10.1016/j.ijrobp.2009.03.010
Koike J, Funahashi K, Yoshimatsu K, Yokomizo H, Kan H, Yamada T, et al. Efficacy and safety of NACT with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial. Cancer Chemother Pharmacol. 2017;79(3):519-525. https://doi.org/10.1007/s00280-017-3243-7
Hasegawa S, Goto S, Matsumoto T, Hida K, Kawada K, Matsusue R, et al. A multicenter phase 2 study on the feasibility and efficacy of NACT without radiotherapy for locally advanced rectal cancer. Ann Surg Oncol. 2017;24(12):3587-3595. https://doi.org/10.1245/s10434-017-5967-3
Kennecke HF, O'Callaghan CJ, Loree JM, Moloo H, Auer R, Jonker DJ, et al. NACT, excision, and observation for early rectal cancer: the phase II NEO trial (CCTG CO.28) primary end point results. J Clin Oncol. 2023;41(2):233-242. https://doi.org/10.1200/jco.22.00184
Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol. 2016;34(27):3300-3307. https://doi.org/10.1200/jco.2016.66.6198
Mei WJ, Wang XZ, Li YF, Sun YM, Yang CK, Lin JZ, et al. NACT with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): initial results of a phase III trial. Ann Surg. 2023;277(4):557-564. https://doi.org/10.1097/sla.0000000000005780
Zhang J, Huang M, Cai Y, Wang L, Xiao J, Lan P, et al. NACT with mFOLFOXIRI without routine use of radiotherapy for locally advanced rectal cancer. Clin Colorectal Cancer. 2019;18(4):238-244. https://doi.org/10.1016/j.clcc.2019.07.001
Deng X, Wu Q, Bi L, Yu Y, Huang S, He D, et al. Early response to upfront NACT (CAPOX) alone in low- and intermediate-risk rectal cancer: a single-arm phase II trial. Br J Surg. 2021;109(1):121-128. https://doi.org/10.1093/bjs/znab388
Glynne-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, et al. Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of NACT alone in patients with high-risk cancer of the rectum. BMC Cancer. 2015;15:764. https://doi.org/10.1186/s12885-015-1764-1
Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, et al. NACT without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32(6):513-518. https://doi.org/10.1200/jco.2013.51.7904
Han YB, Oh SN, Choi MH, Lee SH, Jang HS, Lee MA, et al. Clinical impact of tumor volume reduction in rectal cancer following preoperative chemoradiation. Diagn Interv Imaging. 2016;97(9):843-850. https://doi.org/10.1016/j.diii.2016.05.004
Shiraishi T, Sasaki T, Ikeda K, Tsukada Y, Nishizawa Y, Ito M. Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer. BMC Cancer. 2019;19(1):1222. https://doi.org/10.1186/s12885-019-6424-4
Nougaret S, Castan F, de Forges H, Vargas HA, Gallix B, Gourgou S, et al. Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial. Br J Surg. 2019;106(11):1530-1541. https://doi.org/10.1002/bjs.11233
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363-2376. https://doi.org/10.1056/NEJMoa2201445